Bevacizumab versus ranibizumab in age-related macular degeneratio

Completed

• Conditions: Age-related macular degeneration; Eye Diseases; Other retinal disorders

• Registration Number: ISRCTN73359806
• Lead Sponsor: VA Boston Healthcare System (USA)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-04-30
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 125

Inclusion Criteria

1. Exudative AMD involving the foveal centre confirmed by intravenous fluorescein angiography
2. Aged greater than 50 years, either sex
3. Ability to provide informed consent

Exclusion Criteria

1. Previous treatment for exudative AMD in the past one year
2. Presence of subretinal haemorrhage that is greater than 50% of the size of the lesion
3. Advanced glaucoma
4. Any co-existing macular disease causing decreased vision
5. Uncontrolled hypertension
6. History of thromboembolic phenomenon
7. Participation in another concurrent ophthalmic trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified